Just taking an opportunity to update my views on VIABILITY post...

Just taking an opportunity to update my views on VIABILITY post survey results.
My key concern on degree of effectiveness has been alleviated, achieving results in line with what I'd hoped for, which is probably more than that required by the big device corporations.
Their level of interest was another concern, but now I say why wouldn't they be interested. We have an effective, low risk, easily scaleable product priced to sell into a massive unmet global market using a subscription model with sales supported by multiple population and health trends as well as factors such as likely insurance company support and rebates, and other markets/indications.  We need a tiny fraction of the primary market for great success.
Additionally my concern about management ability is alleviated by the strategic investment of Peter Corr with his exceptional expertise, experience, guidance and contacts; and he will be managing the licensing auction.
It will be a bit painful waiting for that auction though...